Masimo Corp (MASI) 22.03 $MASI
Loss Wider than Ests, Poor Margins at BioScrip; Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 11:50AM CDT
BioScrip, Inc. (BIOS) recently declared its first-quarter 2014 results.
Technical Data on Health Care Sector Equities -- Research on Volcano, Masimo, Wright Medical, and Sirona Dental Systems
PR Newswire - Fri May 09, 11:00AM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Volcano Corporation (NASDAQ: VOLC), Masimo Corporation (NASDAQ: MASI), Wright Medical Group Inc. (NASDAQ: WMGI) and Sirona Dental Systems Inc. (NASDAQ: SIRO). Free technical research on VOLC, MASI, WMGI and SIRO can be downloaded upon signing up at:
Why Masimo (MASI) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:34AM CDT
One such company that might be well-positioned for future earnings growth is Masimo Corporation (MASI).
Abiomed Sees Flat Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 9:00AM CDT
For fiscal 2015, Abiomed (ABMD) forecasted revenues between $205 and $212 million for the year.
Masimo to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Thu May 08, 4:58AM CDT
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference at the Encore at the Wynn Las Vegas on Thursday, May 15, 2014, at 12:40 p.m. Pacific Time. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.
Largest-Ever Study of Newborn Screening for Congenital Heart Disease Again Shows Masimo SET(R) Pulse Oximetry as Effective Tool
Marketwire - Wed May 07, 5:04AM CDT
Masimo (NASDAQ: MASI) today announced that the largest-ever study of newborn screening for congenital heart disease (CHD) was published online by The Lancet. The study of 122,738 newborns -- more than twice as large as any previous study of this type -- was conducted using Masimo SET(R) Measure-through Motion and Low Perfusion(TM) Pulse Oximetry and showed that Masimo SET(R) pulse oximetry screening significantly increased the rate of CHD detection and is "feasible and reliable" for detecting major congenital heart disease.(1)
Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018
M2 - Tue May 06, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bflr6j/patient) has announced the addition of the "Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018" report to their offering. The patient monitoring devices market is segmented into nine major segments, namely, hemodynamic, neurology, cardiac, respiratory, fetal and neonatal, multiparameter, remote patient monitors, temperature, and weight management monitors. The overall patient monitoring devices market was valued as $17.0 billion in 2013 and is poised to grow at a CAGR of 5.5% till 2018. The market is driven by rise in the geriatric population, growing incidences of lifestyle diseases, increased use of home and remote monitors, and technological advancements like portability of equipment. However, the economic crisis and unpredictable reimbursement policies will restrain the growth of this market to an extent. The most fruitful segments for companies to invest in the near future will be neuromonitors, remote patient monitoring (RPM) devices, and respiratory monitors. The cardiac monitors segment is further sub divided into ECG, event monitors, and cardiac output sub segments. ECG was the leading segment owing to expanding old population and growing incidences of cardiac and diseases such as diabetes and hypertension. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Hemodynamic Monitoring Devices 6 Neuromonitoring Devices 7 Cardiac Monitoring Devices 8 Fetal & Neonatal Monitoring Devices 9 Respiratory Monitoring Devices 10 Multi-Parameter Monitoring Devices 11 Remote Patient Monitoring Devices Market 12 Weight Monitoring Devices 13 Temperature Monitoring Devices 14 Geographic Analysis 15 Competitive Landscape 16 Company Profiles Companies Mentioned: - A&D Medical Company Ltd. - AMBU Inc. - Abbott Laboratories - Briggs Healthcare - Cardiocom (Medtronic) - Cardionet, Inc. (Biotelemetry, Inc.) - Carefusion Corporation - Compumedics Limited - Conmed - Contec Medical Systems Co. Ltd. - Covidien - Drager Medical Gmbh - Edwards Lifesciences Corporation - Elekta AB - Fukuda Denshi Company Ltd. - Ge Healthcare - Honeywell International Inc. - Intouch Health - Johnson & Johnson, Inc. - Lifewatch AG - Masimo Corporation - Mindray Medical International Limited - Mortara Instrument, Inc. - Natus - Nihon Kohden - Nonin Medical Inc. - OSI Systems Inc. (Spacelabs Healthcare) - Omron - Robert Bosch Healthcare Inc. - Roche Diagnostics Limited - Royal Philips Healthcare - Schiller AG - Seca Gmbh & Co. Kg. - Siemens Healthcare - Smiths Medical - Welch Allyn - Yokogawa Electric Corporation For more information visit http://www.researchandmarkets.com/research/bflr6j/patient
Masimo Has Returned 12.8% Since SmarTrend Recommendation (MASI)
Comtex SmarTrend(R) - Tue May 06, 9:29AM CDT
SmarTrend identified a Downtrend for Masimo (NASDAQ:MASI) on April 8th, 2014 at $26.46. In approximately 4 weeks, Masimo has returned 12.83% as of today's recent price of $23.06.
Masimo (MASI) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:08AM CDT
Masimo (MASI) is now in Oversold Territory
Masimo Corporation Q1 Earnings Rise, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:22AM CDT
For 2014, Masimo Corporation (MASI) expects revenues of $588 to $598 million, which includes Product revenues of $560 to $570 million and Royalty revenues of $28 million.
Masimo Celebrates 25th Anniversary of Its Incorporation With Major Initiatives to Improve Patient Safety
Marketwire - Fri May 02, 7:02AM CDT
Masimo (NASDAQ: MASI), the innovator of breakthrough patient monitoring technologies clinically shown to saves lives and the eyesight of newborns, and to help clinicians reduce unnecessary medical procedures and make better, faster decisions, today announced it will celebrate its Silver 25th Anniversary with major initiatives to improve patient safety.
Nasdaq stocks posting largest percentage decreases
AP - Thu May 01, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Masimo Reports First Quarter 2014 Financial Results
Marketwire - Wed Apr 30, 3:08PM CDT
Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 29, 2014.
Masimo to Report First Quarter 2014 Financial Results After Market Close on Wednesday, April 30
Marketwire - Thu Apr 17, 7:57AM CDT
Masimo (NASDAQ: MASI) announced today that it will release financial results for the first quarter ended March 29, 2014, after the market closes on Wednesday, April 30, 2014. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
Masimo Reports Encouraging PVI Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 5:40PM CDT
The results demonstrated that MASI's non-invasive PVI parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia.
Healthcare Companies Report Recognitions, Schedules, and Stock Movements - Analyst Notes on WellPoint, Quest Diagnostics, LabCorp, Covance, and Masimo
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corp. of America Holdings (NYSE: LH), Covance Inc. (NYSE: CVD), and Masimo Corporation (NASDAQ: MASI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
New Clinical Study Shows Masimo PVI(R) Helps Clinicians Optimize Fluid Administration in Patients Under Combined General and Epidural Anesthesia
Marketwire - Mon Apr 07, 7:02AM CDT
Masimo (NASDAQ: MASI) announced today a recent study in the Journal of Monitoring and Computing demonstrates that Masimo's noninvasive PVI(R) parameter can help clinicians optimize fluid management and reduce unnecessary fluid administration for abdominal surgical patients under combined general and epidural anesthesia.(1)
Masimo Expands Its Board of Directors With Appointment of Medical Device Executive Craig Reynolds
Marketwire - Fri Apr 04, 4:00AM CDT
Masimo (NASDAQ: MASI), a global innovator of noninvasive patient monitoring technologies, today announced the appointment of seasoned medical device executive Craig B. Reynolds to the Board of Directors of Masimo. Reynolds also will serve as a member of the board's Audit Committee as well as the Compensation Committee.
Global mHealth Market Report 2014: Devices, Applications, Services & Therapeutics 2012 - 2020
M2 - Fri Mar 07, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/994c6r/mhealth_market) has announced the addition of the "Global mHealth Market (Devices, Applications, Services & Therapeutics) 2012 - 2020" report to their offering. The global mHealth market is Expected to Reach $58.8 Billion Globally by 2020 Europe leads the regional market landscape of the global mHealth market followed by Asia Pacific and North America. Furthermore, by 2020, Asia Pacific will take away the lead from North America, occupying more than 28.2% of the market. The players profiled in this report include: Philips healthcare, Omron HealthCare Inc., Bayer Healthcare, LifeWatch, Cardionet Inc., Masimo Corporation, Sanofie, Boston Scientific, AT&T Inc., and Johnson & Johnson. The study observed that the global mHealth market was valued at $6.7 billion in 2012 and is estimated to reach $8.3 billion by the end of 2013. With growing per capita healthcare expenditure both in developed and advanced developing countries. The geography market assessment signifies that Europe along with North America will account for about 55% of the overall market revenue in 2013 and may reduce with growing demand in Asia Pacific region. The study also offers an updated review on the present major market player such as manufacturers of mobile medical devices, and mobile network providers; which also includes description of relevant recent developments activities. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Mobile Healthcare (Mhealth) Market Overview Chapter 4 Global Mobile Healthcare (Mhealth) Market - By Devices Chapter 5 Global Mobile Healthcare (Mhealth) Market - By Service Chapter 6 Global Mobile Healthcare (Mhealth) Market - By Stakeholders Chapter 7 Global Mobile Healthcare (Mhealth) Market - By Therapeutic Segment/Specialty Chapter 8 Global Mobile Healthcare (Mhealth) Market - By Geography Chapter 9 Company Profiles For more information visit http://www.researchandmarkets.com/research/99...lth_market
Loss Wider than Ests, Poor Margins at BioScrip; Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 11:50AM CDT
BioScrip, Inc. (BIOS) recently declared its first-quarter 2014 results.
Technical Data on Health Care Sector Equities -- Research on Volcano, Masimo, Wright Medical, and Sirona Dental Systems
PR Newswire - Fri May 09, 11:00AM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Volcano Corporation (NASDAQ: VOLC), Masimo Corporation (NASDAQ: MASI), Wright Medical Group Inc. (NASDAQ: WMGI) and Sirona Dental Systems Inc. (NASDAQ: SIRO). Free technical research on VOLC, MASI, WMGI and SIRO can be downloaded upon signing up at:
Why Masimo (MASI) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:34AM CDT
One such company that might be well-positioned for future earnings growth is Masimo Corporation (MASI).
Abiomed Sees Flat Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 9:00AM CDT
For fiscal 2015, Abiomed (ABMD) forecasted revenues between $205 and $212 million for the year.
Masimo to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Thu May 08, 4:58AM CDT
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference at the Encore at the Wynn Las Vegas on Thursday, May 15, 2014, at 12:40 p.m. Pacific Time. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.
Largest-Ever Study of Newborn Screening for Congenital Heart Disease Again Shows Masimo SET(R) Pulse Oximetry as Effective Tool
Marketwire - Wed May 07, 5:04AM CDT
Masimo (NASDAQ: MASI) today announced that the largest-ever study of newborn screening for congenital heart disease (CHD) was published online by The Lancet. The study of 122,738 newborns -- more than twice as large as any previous study of this type -- was conducted using Masimo SET(R) Measure-through Motion and Low Perfusion(TM) Pulse Oximetry and showed that Masimo SET(R) pulse oximetry screening significantly increased the rate of CHD detection and is "feasible and reliable" for detecting major congenital heart disease.(1)
Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018
M2 - Tue May 06, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bflr6j/patient) has announced the addition of the "Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018" report to their offering. The patient monitoring devices market is segmented into nine major segments, namely, hemodynamic, neurology, cardiac, respiratory, fetal and neonatal, multiparameter, remote patient monitors, temperature, and weight management monitors. The overall patient monitoring devices market was valued as $17.0 billion in 2013 and is poised to grow at a CAGR of 5.5% till 2018. The market is driven by rise in the geriatric population, growing incidences of lifestyle diseases, increased use of home and remote monitors, and technological advancements like portability of equipment. However, the economic crisis and unpredictable reimbursement policies will restrain the growth of this market to an extent. The most fruitful segments for companies to invest in the near future will be neuromonitors, remote patient monitoring (RPM) devices, and respiratory monitors. The cardiac monitors segment is further sub divided into ECG, event monitors, and cardiac output sub segments. ECG was the leading segment owing to expanding old population and growing incidences of cardiac and diseases such as diabetes and hypertension. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Hemodynamic Monitoring Devices 6 Neuromonitoring Devices 7 Cardiac Monitoring Devices 8 Fetal & Neonatal Monitoring Devices 9 Respiratory Monitoring Devices 10 Multi-Parameter Monitoring Devices 11 Remote Patient Monitoring Devices Market 12 Weight Monitoring Devices 13 Temperature Monitoring Devices 14 Geographic Analysis 15 Competitive Landscape 16 Company Profiles Companies Mentioned: - A&D Medical Company Ltd. - AMBU Inc. - Abbott Laboratories - Briggs Healthcare - Cardiocom (Medtronic) - Cardionet, Inc. (Biotelemetry, Inc.) - Carefusion Corporation - Compumedics Limited - Conmed - Contec Medical Systems Co. Ltd. - Covidien - Drager Medical Gmbh - Edwards Lifesciences Corporation - Elekta AB - Fukuda Denshi Company Ltd. - Ge Healthcare - Honeywell International Inc. - Intouch Health - Johnson & Johnson, Inc. - Lifewatch AG - Masimo Corporation - Mindray Medical International Limited - Mortara Instrument, Inc. - Natus - Nihon Kohden - Nonin Medical Inc. - OSI Systems Inc. (Spacelabs Healthcare) - Omron - Robert Bosch Healthcare Inc. - Roche Diagnostics Limited - Royal Philips Healthcare - Schiller AG - Seca Gmbh & Co. Kg. - Siemens Healthcare - Smiths Medical - Welch Allyn - Yokogawa Electric Corporation For more information visit http://www.researchandmarkets.com/research/bflr6j/patient
Masimo Has Returned 12.8% Since SmarTrend Recommendation (MASI)
Comtex SmarTrend(R) - Tue May 06, 9:29AM CDT
SmarTrend identified a Downtrend for Masimo (NASDAQ:MASI) on April 8th, 2014 at $26.46. In approximately 4 weeks, Masimo has returned 12.83% as of today's recent price of $23.06.
Masimo (MASI) is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 8:08AM CDT
Masimo (MASI) is now in Oversold Territory
Masimo Corporation Q1 Earnings Rise, Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:22AM CDT
For 2014, Masimo Corporation (MASI) expects revenues of $588 to $598 million, which includes Product revenues of $560 to $570 million and Royalty revenues of $28 million.
Masimo Celebrates 25th Anniversary of Its Incorporation With Major Initiatives to Improve Patient Safety
Marketwire - Fri May 02, 7:02AM CDT
Masimo (NASDAQ: MASI), the innovator of breakthrough patient monitoring technologies clinically shown to saves lives and the eyesight of newborns, and to help clinicians reduce unnecessary medical procedures and make better, faster decisions, today announced it will celebrate its Silver 25th Anniversary with major initiatives to improve patient safety.
Nasdaq stocks posting largest percentage decreases
AP - Thu May 01, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Masimo Reports First Quarter 2014 Financial Results
Marketwire - Wed Apr 30, 3:08PM CDT
Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 29, 2014.
Masimo to Report First Quarter 2014 Financial Results After Market Close on Wednesday, April 30
Marketwire - Thu Apr 17, 7:57AM CDT
Masimo (NASDAQ: MASI) announced today that it will release financial results for the first quarter ended March 29, 2014, after the market closes on Wednesday, April 30, 2014. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
Masimo Reports Encouraging PVI Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 5:40PM CDT
The results demonstrated that MASI's non-invasive PVI parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia.
Healthcare Companies Report Recognitions, Schedules, and Stock Movements - Analyst Notes on WellPoint, Quest Diagnostics, LabCorp, Covance, and Masimo
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corp. of America Holdings (NYSE: LH), Covance Inc. (NYSE: CVD), and Masimo Corporation (NASDAQ: MASI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
New Clinical Study Shows Masimo PVI(R) Helps Clinicians Optimize Fluid Administration in Patients Under Combined General and Epidural Anesthesia
Marketwire - Mon Apr 07, 7:02AM CDT
Masimo (NASDAQ: MASI) announced today a recent study in the Journal of Monitoring and Computing demonstrates that Masimo's noninvasive PVI(R) parameter can help clinicians optimize fluid management and reduce unnecessary fluid administration for abdominal surgical patients under combined general and epidural anesthesia.(1)
Masimo Expands Its Board of Directors With Appointment of Medical Device Executive Craig Reynolds
Marketwire - Fri Apr 04, 4:00AM CDT
Masimo (NASDAQ: MASI), a global innovator of noninvasive patient monitoring technologies, today announced the appointment of seasoned medical device executive Craig B. Reynolds to the Board of Directors of Masimo. Reynolds also will serve as a member of the board's Audit Committee as well as the Compensation Committee.
Global mHealth Market Report 2014: Devices, Applications, Services & Therapeutics 2012 - 2020
M2 - Fri Mar 07, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/994c6r/mhealth_market) has announced the addition of the "Global mHealth Market (Devices, Applications, Services & Therapeutics) 2012 - 2020" report to their offering. The global mHealth market is Expected to Reach $58.8 Billion Globally by 2020 Europe leads the regional market landscape of the global mHealth market followed by Asia Pacific and North America. Furthermore, by 2020, Asia Pacific will take away the lead from North America, occupying more than 28.2% of the market. The players profiled in this report include: Philips healthcare, Omron HealthCare Inc., Bayer Healthcare, LifeWatch, Cardionet Inc., Masimo Corporation, Sanofie, Boston Scientific, AT&T Inc., and Johnson & Johnson. The study observed that the global mHealth market was valued at $6.7 billion in 2012 and is estimated to reach $8.3 billion by the end of 2013. With growing per capita healthcare expenditure both in developed and advanced developing countries. The geography market assessment signifies that Europe along with North America will account for about 55% of the overall market revenue in 2013 and may reduce with growing demand in Asia Pacific region. The study also offers an updated review on the present major market player such as manufacturers of mobile medical devices, and mobile network providers; which also includes description of relevant recent developments activities. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Mobile Healthcare (Mhealth) Market Overview Chapter 4 Global Mobile Healthcare (Mhealth) Market - By Devices Chapter 5 Global Mobile Healthcare (Mhealth) Market - By Service Chapter 6 Global Mobile Healthcare (Mhealth) Market - By Stakeholders Chapter 7 Global Mobile Healthcare (Mhealth) Market - By Therapeutic Segment/Specialty Chapter 8 Global Mobile Healthcare (Mhealth) Market - By Geography Chapter 9 Company Profiles For more information visit http://www.researchandmarkets.com/research/99...lth_market
